Clinical Trials Logo

Hepatoma clinical trials

View clinical trials related to Hepatoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02704130 Terminated - Clinical trials for Hepatocellular Carcinoma

TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma

Start date: March 2016
Phase: N/A
Study type: Interventional

This is a single-center, prospective RCT to study the effectiveness of TACE and MWA combination therapy with MWA monotherapy for the treatment of early HCC. Primary outcome is 2-year intrahepatic disease-free survival.

NCT ID: NCT02460991 Terminated - Clinical trials for Hepatocellular Carcinoma

A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma

SOLACE
Start date: November 2015
Phase: Phase 3
Study type: Interventional

This is a prospective, multicenter study that will be conducted at up to 40 centers in the United States and Outside United States (OUS). Participants in the study will be randomly assigned to receive either ONCO-DOX or sorafenib treatment. This study will evaluate the study participants' outcomes (medical condition) after being treated with ONCO-DOX and compare it to those treated with sorafenib alone.

NCT ID: NCT00669136 Terminated - Clinical trials for Hepatocellular Carcinoma

Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma

Start date: June 2009
Phase: Phase 1
Study type: Interventional

To evaluate the safety, toxicity and immunological effects of adjuvant administration of an experimental therapy consisting on priming with three intramuscular administrations of a plasmid expressing human AFP (phAFP) together with a plasmid expressing human GM-CSF (phGM-CSF), followed by a single intramuscular boost with an AFP adenoviral vector (AdVhAFP) to patients with locoregionally pre-treated hepatocellular carcinoma (HCC).

NCT ID: NCT00568308 Terminated - Cancer Clinical Trials

Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma

PATHWAY
Start date: December 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.

NCT ID: NCT00503867 Terminated - Clinical trials for Carcinoma, Hepatocellular

SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma

Start date: July 18, 2007
Phase: N/A
Study type: Interventional

The main purpose of this study is to determine the safety and toxicity of treatment with SIR-Spheres® in patients with unresectable primary liver cancer or hepatocellular carcinoma (HCC). Other purposes of this study include assessment of the effect of treatment on overall survival, the length of time it takes for the disease to worsen, if and how the treatment affects the patient's quality of life, and if and how the cancer responds to the treatment.